Biotech · Private company · Austin, TX, US
Lumos Pharma, Inc.
SEC CIK 0001126234
Track this companyFree. Adds Lumos Pharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials53 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- LUM-201Phase 3 · Growth Hormone Deficiency (GHD)ClinicalTrials.gov · fetched Nov 12, 2026
- LUM-201Phase 2 · Growth Hormone DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- rhGH Norditropin® pen (34 µg/kg)Phase 2 · Growth Hormone DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- NLG802 (indoximod Prodrug)Phase 1 · Progressive Pediatric Brain CancerClinicalTrials.gov · fetched Nov 12, 2026
- TemozolomidePhase 1 · Progressive Pediatric Brain CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain CancerPHASE1 · NOT_YET_RECRUITING · started Oct 8, 2026ClinicalTrials.gov NCT07732413 · fetched Nov 12, 2026
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyPHASE3 · RECRUITING · started May 20, 2026ClinicalTrials.gov NCT06948214 · fetched Nov 12, 2026
- A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)PHASE2 · ENROLLING_BY_INVITATION · started Aug 1, 2023ClinicalTrials.gov NCT05796440 · fetched Nov 12, 2026
- Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)PHASE2 · COMPLETED · started Feb 18, 2022ClinicalTrials.gov NCT05250063 · fetched Nov 12, 2026
- Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)PHASE2 · COMPLETED · started Dec 31, 2020ClinicalTrials.gov NCT04614337 · fetched Nov 12, 2026